US 7,615,209 B2
	Compositions of NDV and methods of use thereof for treatment of cancer
Zichria Zakay-Rones, Jerusalem (Israel); Amos Panet, Mevaseret Zion (Israel); Evgeniya Greenbaum, Jerusalem (Israel); Eithan Galun, Har Adar (Israel); Arnold I. Freeman, Modi'in Ilit (Israel); Linda Rasooly, Jerusalem (Israel); and Charles S. Irving, Caesarea (Israel)
Assigned to Yissum Research Development Company of the Hebrew University of Jerusalem, Jerusalem (Israel); and Theravir Management L.P., Jerusalem (Israel)
Filed on Nov. 20, 2006, as Appl. No. 11/561,510.
Application 11/561510 is a continuation in part of application No. 10/800256, filed on Mar. 11, 2004, granted, now 7,223,389.
Application 10/800256 is a continuation of application No. PCT/IL02/00765, filed on Sep. 12, 2002.
Claims priority of application No. 145397 (IL), filed on Sep. 12, 2001.
Prior Publication US 2007/0128170 A1, Jun. 07, 2007
This patent is subject to a terminal disclaimer.
Int. Cl. A61A 35/00 (2006.01); C12N 15/63 (2006.01)

U.S. Cl. 424—93.1  [424/214.1]

33 Claims

1. A method for inducing regression of a tumor in a subject comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of an isolated oncolytic lentogenic strain of Newcastle Disease Virus (NDV) comprising the nucleotide sequence as set forth in SEQ ID NO:1 and a pharmaceutically acceptable carrier.